The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 39-year-old woman with bipolar I disorder is experiencing a persistent depressive episode despite eight weeks of adequate-dose lithium monotherapy with a serum level of 0.9 mEq/L. Her current depression has lasted four months, with a MADRS score of 32 indicating severe depression. She has no current psychotic features, no mixed features, no active suicidal ideation, and no rapid cycling pattern. Her last manic episode was two years ago, and she has never had an antidepressant-induced manic switch. Her lithium level, renal function, thyroid studies, and metabolic panel are all within normal limits. She has no history of metabolic syndrome. The PMHNP is planning the next step in treatment. Which of the following represents the most appropriate treatment planning approach?
Explanation
For bipolar depression that has not responded to adequate lithium monotherapy, current evidence-based guidelines recommend adding an atypical antipsychotic with demonstrated efficacy for bipolar depression, such as quetiapine or lurasidone, rather than adding an antidepressant or increasing lithium to supratherapeutic levels. Both agents are FDA-approved for this indication with rapid onset of action.
Key Takeaway
Quetiapine and lurasidone are first-line adjunctive agents for lithium-refractory bipolar depression based on FDA approval and robust clinical trial evidence, and should be prioritized over adjunctive antidepressants given the mixed evidence and mood destabilization risks of antidepressants in bipolar disorder.